?PROJECT 1: PET MEASURES OF TAU AND AMYLOID PATHOLOGY. We propose in Project 1 to evaluate Tau PET measures in the entire Harvard Aging Brain Study (HABS) cohort, focusing on testing whether the PET measures of Tau and A? are related to each other and to measures of brain structure and function. This research will facilitate the intense efforts currently underway to develop disease-modifying treatments of Alzheimer's disease (AD), aided by biomarkers of these hallmark lesions that could potentially aid in diagnosis, disease staging, drug development, and treatment monitoring. In the proposed competing continuation, HABS participants will undergo PiB and T807 PET (estimated N=250; acquired in Core C: Imaging Core), with a representative subset (N=100) undergoing longitudinal T807 and FDG PET, in order to achieve the following aims:
Aim 1 : To characterize T807 PET in the HABS cohort in order to determine the anatomy of specific binding, relate binding to age, gender and APOE genotype, and identify suitable standard proxy measures of global burden and/or its stages of longitudinal change.
Aim 2 : To assess the interrelationships of Tau and A? deposition and their differential impact on regional connectivity, synaptic integrity, brain volume, and CSF markers.
Aim 3 : To evaluate the longitudinal change in Tau accumulation in relation to A?, connectivity, synaptic integrity, atrophy, and CSF markers, as well as to longitudinal cognition, coordinating with Project 4. !

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG036694-08
Application #
9242540
Study Section
Special Emphasis Panel (ZAG1-ZIJ-6)
Project Start
Project End
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
8
Fiscal Year
2017
Total Cost
$183,636
Indirect Cost
$77,896
Name
Massachusetts General Hospital
Department
Type
Independent Hospitals
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Rieckmann, Anna; Johnson, Keith A; Sperling, Reisa A et al. (2018) Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. Proc Natl Acad Sci U S A 115:10160-10165
Makaretz, Sara J; Quimby, Megan; Collins, Jessica et al. (2018) Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1024-1031
Lois, Cristina; Gonzalez, Ivan; Johnson, Keith A et al. (2018) PET imaging of tau protein targets: a methodology perspective. Brain Imaging Behav :
d'Oleire Uquillas, Federico; Jacobs, Heidi I L; Biddle, Kelsey D et al. (2018) Regional tau pathology and loneliness in cognitively normal older adults. Transl Psychiatry 8:282
Donovan, Nancy J; Locascio, Joseph J; Marshall, Gad A et al. (2018) Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. Am J Psychiatry 175:530-537
Properzi, Michael J; Buckley, Rachel F; Chhatwal, Jasmeer P et al. (2018) Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. Neuroimage 186:446-454
Hanseeuw, Bernard J; Jonas, Victoria; Jackson, Jonathan et al. (2018) Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry :
Lee, Catherine; Betensky, Rebecca A; Alzheimer's Disease Neuroimaging Initiative (2018) Time-to-event data with time-varying biomarkers measured only at study entry, with applications to Alzheimer's disease. Stat Med 37:914-932
Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431
Chiou, Sy Han; Austin, Matthew D; Qian, Jing et al. (2018) Transformation model estimation of survival under dependent truncation and independent censoring. Stat Methods Med Res :962280218817573

Showing the most recent 10 out of 170 publications